JHVEPhoto/iStock Editorial via Getty Images McKesson (NYSE:MCK) published their Q3 FY24 earnings on February 7th, reporting 15% topline growth and 12.2% adjusted EPS growth. I highlighted their growth opportunities in GLP-1 medications and their significant share buyback program in my introductory coverage. I maintain a 'Strong Buy' rating with a fair value of $660 per share. Strong GLP-1 Growth and Prior Authorization Network In Q3 FY24, McKesson delivered 15% revenue growth on a constant currency basi ...